Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2

[Image: see text] The outbreak of COVID-19 by the end of 2019 has posed serious health threats to humanity and jeopardized the global economy. However, no effective drugs are available to treat COVID-19 currently and there is a great demand to fight against it. Here, we combined computational screen...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ke, Zou, Rongfeng, Cui, Wenqiang, Li, Meiqing, Wang, Xueying, Dong, Junlin, Li, Hongchun, Li, Hongpei, Wang, Peihui, Shao, Ximing, Su, Wu, Chan, H. C. Stephen, Li, Hongchang, Yuan, Shuguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671100/
https://www.ncbi.nlm.nih.gov/pubmed/34778724
http://dx.doi.org/10.1021/acsptsci.0c00163
Descripción
Sumario:[Image: see text] The outbreak of COVID-19 by the end of 2019 has posed serious health threats to humanity and jeopardized the global economy. However, no effective drugs are available to treat COVID-19 currently and there is a great demand to fight against it. Here, we combined computational screening and an efficient cellular pseudotyped virus system, confirming that clinical HDAC inhibitors can efficiently prevent SARS-CoV-2 and potentially be used to fight against COVID-19.

Ejemplares similares